Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 19/20 | 0.47 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10075560 | 0.86 | S1PR3 (0.51) | S1PR3PLA2G2APLA2G1B | |
| SCHEMBL337020 | 0.85 | S1PR3 (0.59) | S1PR3PLA2G2A | |
| SCHEMBL336487 | 0.83 | S1PR3 (0.50) | S1PR3PLA2G2APLA2G1B | |
| SCHEMBL337528 | 0.82 | S1PR3 (0.51) | S1PR3PLA2G2APLA2G1B | |
| SCHEMBL8235376 | 0.81 | RAD52 (0.55) | S1PR3 | |
| SCHEMBL336683 | 0.78 | S1PR3 (0.44) | S1PR3PLA2G2APLA2G1B | |
| SCHEMBL336682 | 0.78 | S1PR3 (0.44) | S1PR3PLA2G2APLA2G1B | |
| SCHEMBL336719 | 0.76 | S1PR3 (0.53) | S1PR3PLA2G2APLA2G1B | |
| SCHEMBL336644 | 0.73 | PLA2G2A (0.61) | S1PR3PLA2G2APLA2G1B | |
| SCHEMBL337183 | 0.71 | PLA2G2A (0.59) | S1PR3PLA2G2APLA2G1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097644-B2 | Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | ALLERGAN, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| WO-2007112322-A2 | INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
| WO-2007112322-A2 | INDOLE COMPOUNDS HAVING SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR AGONIST AND/OR ANTAGONIST BIOLOGICAL ACTIVITY | ALLERGAN, INC. (US) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232682-A1 | Indole Compounds having sphingosine-1-phosphate (S1P) receptor antagonist | S1PR1, S1PR2, S1PR3 | S1PR3 3/4885PLA2G2A 630/4885PLA2G1B 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.